Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation‐perfusion relationships and central haemodynamics in healthy subjects,
- 1 November 1993
- journal article
- Published by Wiley in Clinical Physiology and Functional Imaging
- Vol. 13 (6) , 677-685
- https://doi.org/10.1111/j.1475-097x.1993.tb00482.x
Abstract
Summary. Ventilation-perfusion relationships of the lung (VA/Q) and central haemodynamics were studied in nine healthy subjects before and during 30 min of vasoactive intestinal polypeptide (VIP) infusion (20 ng kg-min-1). During the infusion, arterial concentrations of VIP rose from 16-1 6-1 to 420 110 pmol 1-1 and noradrenaline concentrations doubled (P < 0–01). VA/Q distributions, determined by inert gas elimination technique, were significantly shifted to lower values for VA/Q with slight increases in dispersions, but arterial oxygen tension remained unchanged. Heart rate, stroke volume and cardiac output rose 27, 44 and 80% respectively (P < 0–01). Systematic arterial pressure stabilized at a slightly lower level compared to basal (base line: 93 5 mmHg, VIP: 88 6 mmHg, P < 0–05). Right atrial and pulmonary capillary wedge pressures remained unchanged during VIP infusion, while pulmonary vascular resistance and systematic vascular resistance decreased significantly, by 25% (P < 0–03) and 53% (P < 0–01), respectively. It is concluded that VIP causes: (1) alterations in ventilation-perfusion distributions, but generates no shunt and does not cause hypoxaemia during 30 min infusion, (2) reduction of pulmonary and systemic vascular resistances and afterload reduction of the left ventricle, (3) reflex sympathoadrenal stimulation with increasing heart rate and myocardial contractility, and (4) a direct positive inotropic effect on the myocardium.Keywords
This publication has 25 references indexed in Scilit:
- Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: Evidence for a hepatopulmonary syndromeHepatology, 1990
- Cardiovascular effects of vasoactive intestinal peptide in healthy subjectsThe American Journal of Cardiology, 1987
- Plasma neuropeptide Y‐like immunoreactivity and catecholamines during various degrees of sympathetic activation in manClinical Physiology and Functional Imaging, 1986
- Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathologyPeptides, 1984
- Circulatory effects of VIP in anesthetized manPeptides, 1984
- Vasoactive Intestinal Peptide (VIP) and peptide having N-terminal histidine and C-terminal isoleucine amide (PHI) stimulate adenylate cyclase activity in human heart membranesPeptides, 1982
- Vasoactive Intestinal Polypeptide (VIP) in Cirrhosis: Arteriovenous Extraction in Different Vascular BedsScandinavian Journal of Gastroenterology, 1980
- Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: Comparison with a radioenzymatic methodLife Sciences, 1979
- Afterload mismatch and preload reserve: A conceptual framework for the analysis of ventricular functionProgress in Cardiovascular Diseases, 1976
- Polypeptide with Broad Biological Activity: Isolation from Small IntestineScience, 1970